Trial Profile

A Phase Ib extension study to evaluate IkT-148009 in Parkinson's patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Apr 2022 According to an Inhibikase Therapeutics media release, the company will host a virtual KOL investor event. Presentations will highlight recently presented Phase 1 and Phase 1b data for IkT-148009 for the treatment of Parkinson's disease.
31 Mar 2022 According to an Inhibikase Therapeutics media release, the company expects to complete dosing of the Phase 1b study in the second quarter of 2022 and present full data at a medical meeting later this year.
05 Jan 2022 According to a Inhibikase Therapeutics media release, Inhibikase expects to complete enrollment and analysis of the first two cohorts of 8 patients with mild to moderate Parkinson's disease in the first quarter of 2022, with the third cohort completed in the second quarter of 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com